Evidence map›Paper›PMID 31697649›Full record

Trial reportThe Journal of clinical investigation2020

Follicular T helper cells shape the HCV-specific CD4+ T cell repertoire after virus elimination.

Maike Smits, Katharina Zoldan, Naveed Ishaque, Zuguang Gu, Katharina Jechow, Dominik Wieland, Christian Conrad, Roland Eils, Catherine Fauvelle, Thomas F Baumert and 6 more

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in The Journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Hepatitis C virus modifiedJournal of virology · 2025
    Article
  3. Review
  4. CD4 T cells and B cell help - when exhausted cells can still function.JHEP reports : innovation in hepatology · 2025
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Interleukin-21 in Viral Infections.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Maike SmitsDepartment of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Katharina ZoldanDepartment of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Naveed IshaqueDigital Health Center, Berlin Institute of Health (BIH) and Charité Universitätsmedizin, Berlin, Germany.
Zuguang GuGerman Cancer Research Center (DKFZ), Heidelberg, Germany.
Katharina JechowDigital Health Center, Berlin Institute of Health (BIH) and Charité Universitätsmedizin, Berlin, Germany.
Dominik WielandDepartment of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Christian ConradDigital Health Center, Berlin Institute of Health (BIH) and Charité Universitätsmedizin, Berlin, Germany.
Roland EilsDigital Health Center, Berlin Institute of Health (BIH) and Charité Universitätsmedizin, Berlin, Germany.
Catherine FauvelleInstitut de Recherche sur les Maladies Virales et Hépatiques, Inserm U1110, University of Strasbourg, Strasbourg, France.
Thomas F BaumertInstitut de Recherche sur les Maladies Virales et Hépatiques, Inserm U1110, University of Strasbourg, Strasbourg, France.
Florian EmmerichFaculty of Medicine, University of Freiburg, Freiburg, Germany.
Bertram BengschDepartment of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Christoph Neumann-HaefelinDepartment of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Maike HofmannDepartment of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Robert ThimmeDepartment of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Tobias BoettlerDepartment of Medicine II, University Hospital Freiburg, Freiburg, Germany.
University of Freiburg · DEGerman Cancer Research Center · DEInserm · FR

Funding

Project 2 - FranceU19AI123862 · NIAID · STANFORD UNIVERSITY · PI FOUNG, STEVEN · 2016 to 2020
$3.9M
European Research Council 671231NIAID NIH HHS U19 AI123862
6 · The paper itself

Abstract

BACKGROUNDChronic hepatitis C virus (HCV) infection is characterized by a severe impairment of HCV-specific CD4+ T cell help that is driven by chronic antigen stimulation. We aimed to study the fate of HCV-specific CD4+ T cells after virus elimination.METHODSHCV-specific CD4+ T cell responses were longitudinally analyzed using MHC class II tetramer technology, multicolor flow cytometry, and RNA sequencing in a cohort of patients chronically infected with HCV undergoing therapy with direct-acting antivirals. In addition, HCV-specific neutralizing antibodies and CXCL13 levels were analyzed.RESULTSWe observed that the frequency of HCV-specific CD4+ T cells increased within 2 weeks after initiating direct-acting antiviral therapy. Multicolor flow cytometry revealed a downregulation of exhaustion and activation markers and an upregulation of memory-associated markers. Although cells with a Th1 phenotype were the predominant subset at baseline, cells with phenotypic and transcriptional characteristics of follicular T helper cells increasingly shaped the circulating HCV-specific CD4+ T cell repertoire, suggesting antigen-independent survival of this subset. These changes were accompanied by a decline of HCV-specific neutralizing antibodies and the germinal center activity.CONCLUSIONWe identified a population of HCV-specific CD4+ T cells with a follicular T helper cell signature that is maintained after therapy-induced elimination of persistent infection and may constitute an important target population for vaccination efforts to prevent reinfection and immunotherapeutic approaches for persistent viral infections.FUNDINGDeutsche Forschungsgemeinschaft (DFG, German Research Foundation), the National Institute of Allergy and Infectious Diseases (NIAID), the European Union, the Berta-Ottenstein-Programme for Advanced Clinician Scientists, and the ANRS.

Indexed as

Antiviral AgentsFemaleFlow CytometryFollow-Up StudiesHepacivirusHepatitis C, ChronicHumansMaleMiddle AgedTh1 CellsAntiviral AgentsAdaptive immunityCellular immune responseImmunologyInfectious diseaseMHC class 2

Identifiers

PMID31697649
PMCPMC6994124
OpenAlexW2984571636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.